These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36622773)

  • 21. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
    Carlino MS; Gowrishankar K; Saunders CA; Pupo GM; Snoyman S; Zhang XD; Saw R; Becker TM; Kefford RF; Long GV; Rizos H
    Mol Cancer Ther; 2013 Jul; 12(7):1332-42. PubMed ID: 23645591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
    Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
    Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
    Krebs FS; Moura B; Missiaglia E; Aedo-Lopez V; Michielin O; Tsantoulis P; Bisig B; Trimech M; Zoete V; Homicsko K
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
    Johnson DB; Childress MA; Chalmers ZR; Frampton GM; Ali SM; Rubinstein SM; Fabrizio D; Ross JS; Balasubramanian S; Miller VA; Stephens PJ; Sosman JA; Lovly CM
    Pigment Cell Melanoma Res; 2018 May; 31(3):432-436. PubMed ID: 29171936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [